Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New EU Portal To Track Pricing & Reimbursement Applications

Move Will Help Uncover Root Causes Of Medicines Unavailability & Patient Access Delays

Executive Summary

To improve patient access to approved drugs, European R&D-based companies have pledged to apply for pricing and reimbursement of drugs in all EU member states within two years of product approval. A new portal set up by EFPIA will track the progress of these applications, documenting reasons for pricing delays and barriers. 

You may also be interested in...



The Implications Of The New EU HTA Regulation For Companies

Legal and industry expert Alexander Natz sets out key questions and answers to help companies prepare for new EU regulations on health technology assessments, one of the biggest developments to affect the pharmaceutical industry in over a decade.

EU Legislators Firm Up Commission’s Plans To Overhaul Pharma Rules

Efforts to overhaul the EU pharmaceutical legislation have been given added impetus after the European Parliament called for action to boost innovation and medicines access, shore up manufacturing and supply chains, and examine the link between R&D spending and drug prices.

Saudi FDA Finalizes Approach To Commercial Info In Public Assessment Reports

Saudi Arabia has explained what information on a drug’s review will be made public following a marketing authorization decision. 

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS146004

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel